Honasa Consumer, the listed parent of Mamaearth, The Derma Co, and BBlunt, has terminated its proposed acquisition of a 58% stake in nutraceuticals company Fluence Pharma. The deal, first announced in June at an enterprise value of ₹135 crore, was called off on August 25 after what Honasa disclosed as non-fulfilment of closing conditions in the share purchase agreement - without specifying which conditions went unmet. The company has said it will keep exploring both organic and inorganic routes into nutraceuticals.
Honasa’s model has always been a house of brands rather than a single brand stretched across categories: acquire or build distinct labels for distinct customer needs, run them under one balance sheet, and let each brand keep its own identity instead of forcing a single master brand to cover skincare, haircare, and now potentially supplements. Nutraceuticals was a logical adjacency for a beauty-and-personal-care house looking for its next leg of growth post-IPO, and an acquisition is the fastest way to get category credibility without spending years building it from zero.
The part of the story that isn’t the failure
A called-off acquisition usually reads as a setback in coverage built around momentum. It’s worth looking at the opposite way. A house-of-brands strategy only stays coherent if the parent is willing to reject an adjacency that doesn’t clear its own bar, even after the deal has been announced and the market has already priced in the expectation. Walking back a public commitment costs more in perception than never having announced it - which is exactly why most companies push a wobbling deal through rather than admit the diligence uncovered something that didn’t hold up.
Why this matters more for a multi-brand house than a single-brand one
A single-brand company that stretches into a bad adjacency dilutes one asset. A multi-brand house that acquires a bad adjacency adds a permanent liability to a portfolio that depends on every piece meeting the same bar - because the entire pitch to investors is that each brand in the house is a disciplined, category-specific bet, not a grab bag. For a company built on that promise, the more expensive mistake isn’t the ₹135 crore deal that didn’t happen. It’s the one that would have closed anyway.